Revenue distribution by sectors:

• Pharmaceutical products: approx. 85%
• Generics: approx. 10%
• Specialty pharmaceuticals: approx. 5%

TOP 3 markets and their percentage shares:

• USA: approx. 30%
• India: approx. 25%
• Europe: approx. 15%

Sun Pharmaceutical Industries Limited generates the majority of its revenue from pharmaceutical products, with generics and specialty pharmaceuticals also making significant contributions. The U.S. market is the largest single market for the company, followed by India and Europe. These markets are crucial for the growth and strategic direction of the company.

Production sites of Sun Pharmaceutical Industries Limited:

Sun Pharmaceutical Industries Limited operates production facilities in several countries worldwide. The most important production sites include:

• India: The majority of the production capacities are located in India, where the company operates several plants.
• USA: Sun Pharma also has significant production facilities in the United States.
• Canada, Mexico, Brazil: Additional production sites are located in these countries to serve the North and South American markets.
• Europe: In Europe, Sun Pharma owns production plants in countries such as Romania and Hungary.
• Rest of the world: Furthermore, there are production sites in countries like Egypt, South Africa, Malaysia, and Australia.

This global presence enables Sun Pharma to efficiently produce a wide range of pharmaceutical products and distribute them worldwide. The strategic distribution of production sites helps the company better serve local markets and meet regulatory requirements.

Revenue growth: 9.8% (2024) Research and development investments: 7.5% of revenue (2024)

Sun Pharmaceutical Industries Limited pursues a growth strategy that is strongly focused on research and development (R&D). The company continuously invests in the development of new and innovative drugs to expand its product pipeline and strengthen its market position.

Another focus is on geographical expansion, especially in emerging markets, to tap into new markets and increase global presence. This is supported by strategic partnerships and acquisitions that enable Sun Pharma to diversify its product range and leverage synergies.

In addition, the company is focusing on optimizing its production processes to increase efficiency and reduce costs. This is intended to enhance competitiveness and increase margins, ultimately contributing to stable revenue and profit growth in the long term.

Main raw materials: Active ingredients (APIs), excipients, packaging materials

Import countries: China, USA, Germany, Italy

Sun Pharmaceutical Industries Limited mainly imports active ingredients (APIs) that are essential for the production of their pharmaceutical products. A significant portion of these active ingredients comes from China, which is considered one of the largest suppliers of APIs worldwide.

In addition, Sun Pharma sources excipients and packaging materials from various countries, including the USA, Germany, and Italy. These materials are necessary to ensure the quality and effectiveness of the end products.

Relying on imports, especially from China, is a strategic decision to optimize costs and ensure access to high-quality raw materials.

Market share in India: approx. 8.2% (2023)
R&D expenses: 7.3% of revenue (2023)
Global revenue: 5.1 billion USD (2023)

Sun Pharmaceutical Industries Limited has a significant competitive advantage, especially in the Indian market, where it is considered one of the leading pharmaceutical companies. With a market share of about 8.2% in India, Sun Pharma is well positioned to benefit from the growing demand for pharmaceutical products in the region.

The company continuously invests in research and development, as evidenced by the R&D expenses of 7.3% of revenue in 2023. These investments enable Sun Pharma to develop innovative products and expand its product pipeline, making a significant contribution to strengthening its competitive advantage.

On a global scale, Sun Pharma achieves a revenue of 5.1 billion USD, indicating a strong international presence. Diversification into various markets and the ability to offer generic as well as specialized medicines also contribute to their competitive advantage.

Institutional Investor Share: approx. 22% (2025, estimated)

Insider Purchases/Sales: No significant transactions reported (2025, estimated)

The institutional investor share in Sun Pharmaceutical Industries Limited is around 22%. This indicates a moderate interest from institutional investors, suggesting confidence in the company's long-term stability and growth potential.

In 2025, no significant insider purchases or sales were reported. This could suggest that the management and other insiders currently do not expect significant changes in the company's value.

Market share of Sun Pharmaceutical Industries Limited: 8% (estimated, 2025)

Top competitors and their market shares:

1. Cipla Limited: 10% (2025)
2. Dr. Reddy's Laboratories: 9% (2025)
3. Sun Pharmaceutical Industries Limited: 8% (2025)
4. Lupin Limited: 7% (2025)
5. Aurobindo Pharma: 6% (2025)
6. Zydus Cadila: 5% (2025)
7. Torrent Pharmaceuticals: 4% (2025)
8. Biocon Limited: 3% (2025)
9. Glenmark Pharmaceuticals: 3% (2025)
10. Alkem Laboratories: 2% (2025)

Moat of Sun Pharmaceutical Industries Limited:

Sun Pharmaceutical Industries Limited has a moderate moat, mainly supported by its strong brand recognition, wide product portfolio, and global presence. The company benefits from its ability to manufacture cost-effective generic drugs and distribute them in various international markets.

Compared to its competitors, Sun Pharma has an advantage in scale efficiency and R&D investment, leading to a continuous pipeline of new products. However, some competitors, such as Cipla and Dr. Reddy's, also have strong moats through specialized product lines and strategic partnerships.

Competition in the pharmaceutical industry is intense, and many companies heavily invest in research and development as well as strategic alliances to strengthen their market position. Therefore, Sun Pharma's moat is significant but not insurmountable compared to its main competitors.

Revenue growth: 10% (2024) Research and development expenses: 8% of revenue (2024) Market share in the Indian pharmaceutical industry: 8% (2024)

Sun Pharmaceutical Industries Limited recorded a revenue growth of 10% in 2024, attributed to strong demand for its products and successful expansion in international markets. The company continuously invests in research and development, with 8% of revenue allocated to this area. This indicates a strategic focus on developing innovative products and strengthening competitiveness.

With an 8% market share in the Indian pharmaceutical industry, Sun Pharma positions itself as one of the leading players in one of the fastest-growing pharmaceutical markets globally. This market position provides a solid foundation for further growth and expansion.

Overall, the financial and strategic position of Sun Pharmaceutical Industries Limited suggests that the stock could have long-term potential for investors, particularly through its focus on research and international expansion.

Dividend yield: 1.2% (2024) Dividend growth: 5% (last 3 years)

Sun Pharmaceutical Industries Limited regularly pays a dividend to its shareholders. The dividend yield was around 1.2% in 2024. Over the last three years, the company has achieved an average dividend growth of 5%.

The reliability of dividend payments is relatively high as Sun Pharma demonstrates stable financial performance and consistently generates profits. The company has proven in the past that it is capable of maintaining its dividend policy, even in economically challenging times.